Gene transfer of hepatocyte growth factor with prostacyclin synthase in severe pulmonary hypertension of rats

Ono, Masamichi; Sawa, Yoshiki; Fukushima, Norihide; Suhara, Hitoshi; Nakamura, Toshikazu; Yokoyama, Chieko; Tanabe, Tadashi; Matsuda, Hikaru
December 2004
European Journal of Cardio-Thoracic Surgery;Dec2004, Vol. 26 Issue 6, p1092
Academic Journal
Abstract: Objective: Hepatocyte growth factor (HGF) is a multi-potent growth factor, which has anti-fibrotic effects for lung injuries. In this study, we investigated whether human HGF gene transfer may attenuate the medial hypertrophy of pulmonary arteries and enhance the ameliorating effect of prostacyclin in monocrotaline (MCT)-induced pulmonary hypertension in rats. Methods and results: The day before MCT injection, HVJ-liposome complex with the cDNA encoding HGF gene (H group), PGIS gene (P group), and both HGF and PGIS gene (HP group) were transfected to the liver of rats as drug delivery system for the lung. Rats transfected with control vector served as controls (C group). Twenty-eight days after MCT injection, histological examination showed marked thickening of medial wall of pulmonary arteries and right ventricular hypertrophy. Percent medial wall thickness (%WT) of peripheral pulmonary arteries, pressure ratio of the right ventricle (RV) to the left ventricle (LV), and weight ratio of the RV to the LV plus septum were significantly increased in the control. Percent medial wall thickness was significantly ameliorated in H group and HP group in comparison with C group. Pressure and weight ratio of RV to LV was significantly ameliorated in P group and HP group in comparison with C group, and was significantly ameliorated in HP group than P group. Conclusions: In vivo gene transfection with HGF gene attenuated the medial hypertrophy of pulmonary arteries and enhanced the ameliorating effect of prostacyclin for pulmonary hypertension in MCT rats. Thus, gene therapy with HGF and PGIS may be a promising strategy for severe pulmonary hypertension.


Related Articles

  • Comparison of pulmonary vascular function and structure in early and established hypoxic pulmonary hypertension in rats. Jeffery, Trina K; Wanstall, Janet C // Canadian Journal of Physiology & Pharmacology;Mar2001, Vol. 79 Issue 3, p227 

    In pulmonary hypertension, changes in pulmonary vascular structure and function contribute to the elevation in pulmonary artery pressure. The time-courses for changes in function, unlike structure, are not well characterised. Medial hypertrophy and neomuscularisation and reactivity to vasoactive...

  • Foreword.  // Current Medical Literature: Pulmonary Hypertension;2012, Vol. 3 Issue 1, pIV 

    A foreword to the "Current Medical Literature: Pulmonary Hypertension" is presented.

  • Empowered Patient Online Toolkit.  // Advances in Pulmonary Hypertension;Summer2012, Vol. 11 Issue 2, p104 

    The article recommends the comprehensive Empowered Patient Toolkit for patients with pulmonary hypertension by Pulmonary Hypertension Association (PHA).

  • Survival in Patients with Primary Pulmonary Hypertension. D'Alonzo, Gilbert F.; Barst, Robyn J.; Ayres, Stephen M.; Bergofsky, Edward H.; Brundage, Bruce H.; Detre, Katherine M.; Fishman, Alfred P.; Goldring, Roberta M.; Groves, Berton M.; Kernis, Janet T.; Levy, Paul S.; Pietra, Giuseppe G.; Reid, Lynne M.; Reeves, John T.; Rich, Stuart; Vreim, Carol E.; Williams, George W.; Wu, Margaret // Annals of Internal Medicine;9/1/91, Vol. 115 Issue 5, p343 

    Presents information on a study that characterized mortality in persons diagnosed with primary pulmonary hypertension and investigated factors associated with survival. Research methods; Results and discussion on the study; Conclusions.

  • S1P4 receptor mediates S1P-induced vasoconstriction in normotensive and hypertensive rat lungs. Ota, Hiroki; Beutz, Michelle A.; Ito, Masako; Abe, Kohtaro; Oka, Masahiko; McMurtry, Ivan F. // Pulmonary Circulation;2011, Vol. 1 Issue 3, p399 

    This study aimed to identify receptors mediating sphingosine-1-phosphate (S1P)-induced vasoconstriction in the normotensive and chronic hypoxia-induced hypertensive rat pulmonary circulation. In isolated perfused lungs from normoxic rats, infusion of S1P caused a sustained vasoconstriction,...

  • CPU 86017, p-chlorobenzyltetrahydroberberine chloride, attenuates monocrotaline-induced pulmonary hypertension by suppressing endothelin pathway. Zhang, Tian-tai; Cui, Bing; Dai, De-zai; Su, Wei // Acta Pharmacologica Sinica;Nov2005, Vol. 26 Issue 11, p1309 

    Aim: To elucidate the involvement of the endothelin (ET) pathway in the pathogenesis of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) and the therapeutic effect of CPU 86017 ( p-chlorobenzyltetrahydroberberine chloride) in rats. Methods: Rats were injected with a single dose...

  • The endothelin system in pulmonary hypertension. Michel, Rene P.; Langleben, David; Dupuis, Jocelyn // Canadian Journal of Physiology & Pharmacology;Jun2003, Vol. 81 Issue 6, p542 

    Pulmonary hypertension (PH) may result from numerous clinical entities affecting the pulmonary circulation primarily or secondarily. It is recognized that vascular endothelial dysfunction contributes to the development and perpetuation of PH by creating an imbalance between vasodilating and...

  • Inhaled epoprostenol therapy for pulmonary hypertension: Improves oxygenation index more consistently in neonates than in older children. Brown, Anna T.; Gillespie, Jennifer V.; Miquel-Verges, Franscesca; Holmes, Kathryn; Ravekes, William; Spevak, Philip; Brady, Ken; Blaine Easley, R.; Christopher Golden, W.; McNamara, LeAnn; Veltri, Michael A.; Lehmann, Christoph U.; McMillan, Kristen Nelson; Schwartz, Jamie M.; Romer, Lewis H. // Pulmonary Circulation;2012, Vol. 2 Issue 1, p61 

    The purpose of this study was to determine the efficacy of inhaled epoprostenol for treatment of acute pulmonary hypertension (PH) in pediatric patients and to formulate a plan for a prospective, randomized study of pulmonary vasodilator therapy in this population. Inhaled epoprostenol is an...

  • No doctor is an island. Yuan, Jason X. -J.; Morrell, Nicholas W.; Harikrishnan, S.; Butrous, Ghazwan // Pulmonary Circulation;2011, Vol. 1 Issue 4, p435 

    An introduction is presented in which the editor discusses various reports within the issue on topics including the global awareness of pulmonary vascular disease, the relationship of high altitudes with pulmonary circulation, and abstracts from the 2011 Grover Conference.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics